Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug After U.S. Approval
Signage is on display outside the Food and Drug Administration (FDA) headquarters in White Oak, Maryland, US, Aug. 29, 2020. REUTERS/Andrew Kelly/File Photo Register now for FREE unlimited access to Reuters.com Register Aug 17 (Reuters) – The U.S. Food and Drug Administration on Wednesday approved bluebird bios (BLUE.O) gene therapy for patients with a rare …
Bluebird’s $2.8M Gene Therapy Becomes Most Expensive Drug After U.S. Approval Read More »